Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline

Executive Summary

The agency was expecting many pending generic drug submissions to be withdrawn because sponsors would not want to pay the one-time backlog fee, but instead saw a substantial increase near the end of FY 2012.


Related Content

'Bridging' Of Generic Review Goal Dates Makes Progress At US FDA
There's The Bolus! ANDA Sponsors Race To Avoid User Fee Spike
Is ANDA Bolus Coming As Higher User Fees Loom?
Mylan Sees A Difference In Having Generic Drug User Fees
FDA Meets ANDA Backlog Goal Early, Still Doesn't Feel Out Of Woods
FDA To ANDA Sponsors: Don't Forget Quality When Rushing For 10-Month Review Goal
As GDUFA Launch Nears, Is Sitting In The Backlog More Appealing?
GDUFA Guidance Offers Peek At Generic Drug User Fee Levels
FDA Explains How Generic Firms Will Self-Identify Facilities Under New User Fee Program
ANDA User Fees: Negotiators Close To Agreement, But Backlog Is Sticking Point


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts